Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000662 · ClinicalTrials.gov registry record · NA
A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
NCT00000662: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000662 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000662, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count \< 400 cells/mm3 and to monitor adverse effects of AZT. Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT.
Interventions
- DRUG Zidovudine
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 1993-05 |
| Phase | NA |
What the finished NCT00000662 record still lists
NCT00000662 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Zidovudine is the first listed.
NCT00000662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000662 about?
NCT00000662 is a clinical study titled "A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease". To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count \< 400 cells/mm3 and to monitor adverse effects of AZT. Previous studies with pediatric patients have shown improvements in clinical, immuno...
What is the current status of trial NCT00000662?
This trial is currently completed. It is a NA study. Estimated completion is 1993-05.
What interventions are being tested in trial NCT00000662?
The interventions under investigation include: Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00000662?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.